Zai LabZLAB +0.76%64 FCF Margin % is -34.34% as of Mar. 2026. GuruFocus rates ZLAB with a GF Score™ of 64/100 and a GF Value™ of $30.30 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 959 Biotechnology companies, Zai Lab ranks better than 59.85% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Zai Lab's Free Cash Flow for the
three
months ended in Mar. 2026 was $-34.2 Mil. Zai Lab's Revenue for the
three
months ended in Mar. 2026 was $99.6 Mil. Therefore, Zai Lab's FCF Margin % for the quarter that ended in Mar. 2026 was -34.34%.
The historical rank and industry rank for Zai Lab's FCF Margin % or its related term are showing as below:
ZLAB'
s FCF Margin % Range Over the Past 10 Years
Min: -83454.26 Med: -288.15 Max: -29.31
Current: -29.31
During the past 11 years, the highest FCF Margin % of Zai Lab was -29.31%. The lowest was -83454.26%. And the median was -288.15%.
ZLAB's FCF Margin % is ranked better than 59.85% of 959
companies
in the Biotechnology industry
Industry Median: -84.65
vs ZLAB: -29.31
Zai Lab FCF Margin % Related Terms
Zai Lab FCF Margin % Historical Data
* Premium members only.
The historical data trend for Zai Lab's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Zai Lab's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zai Lab FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zai Lab's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Zai Lab's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zai Lab (ZLAB) has a FCF Margin % of -34.34% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Zai Lab and its competitors. According to the industry distribution chart, Zai Lab ranks #385 out of 959 companies in the Biotechnology industry, placing it in the top 40.1%.
Is Zai Lab's FCF Margin % too high?
Zai Lab's current FCF Margin % is -34.34%. Based on the distribution chart, Zai Lab ranks #385 out of 959 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zai Lab has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zai Lab's FCF Margin % compare to TYRA and TRVI?
According to the Biotechnology industry distribution chart, Zai Lab ranks #385 out of 959 companies for FCF Margin %. This puts Zai Lab in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Zai Lab and its competitors. Zai Lab's current FCF Margin % is -34.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zai Lab stock overvalued right now?
Based on GuruFocus' analysis, Zai Lab (ZLAB) is currently considered Possible Value Trap. The stock's GF Value™ is $30.30, compared to a current price of $18.52 — trading 38.9% below its estimated fair value. The current FCF Margin % is -34.34%. Zai Lab's overall GF Score™ is 64/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Zai Lab (ZLAB), the current FCF Margin % is -34.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zai Lab (ZLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Zai Lab stock appears to be undervalued.
The current stock price of $18.52 is trading 38.9% below its estimated GF Value™ of $30.30.
GuruFocus considers Zai Lab to be Possible Value Trap.
Key valuation signals for ZLAB:
FCF Margin %: -34.34%
GF Value™: $30.30 vs. price of $18.52 (38.9% below fair value)
No single metric tells the full story. See the ZLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
64GF Score
Get the complete analysis for ZLAB
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLAB has been successfully added to your 
